Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.

Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P.

BMJ Open. 2018 Jul 25;8(7):e022409. doi: 10.1136/bmjopen-2018-022409.

2.

Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.

Maruani A, Boccara O, Bessis D, Guibaud L, Vabres P, Mazereeuw-Hautier J, Barbarot S, Chiaverini C, Blaise S, Droitcourt C, Mallet S, Martin L, Lorette G, Woillard JB, Jonville-Bera AP, Rollin J, Gruel Y, Herbreteau D, Goga D, le Touze A, Leducq S, Gissot V, Morel B, Tavernier E, Giraudeau B; Groupe de Recherche de la Societé Française de Dermatologie Pédiatrique.

Trials. 2018 Jun 27;19(1):340. doi: 10.1186/s13063-018-2725-1.

3.

Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts.

Gruel Y.

Lancet Haematol. 2018 May;5(5):e188-e189. doi: 10.1016/S2352-3026(18)30050-4. No abstract available.

PMID:
29703334
4.

Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms.

Narata AP, Amelot A, Bibi R, Herbreteau D, Angoulvant D, Gruel Y, Janot K.

Neurosurgery. 2018 Feb 26. doi: 10.1093/neuros/nyy002. [Epub ahead of print]

PMID:
29490066
5.

Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR).

Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; French Working Group on perioperative hemostasis (GIHP).

Arch Cardiovasc Dis. 2018 Mar;111(3):210-223. doi: 10.1016/j.acvd.2017.12.004. Epub 2018 Feb 3. Review. No abstract available.

PMID:
29402671
6.

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.

Touzé E, Gruel Y, Gouin-Thibault I, De Maistre E, Susen S, Sie P, Derex L.

Eur J Neurol. 2018 May;25(5):747-e52. doi: 10.1111/ene.13582. Epub 2018 Mar 9.

PMID:
29360254
7.

Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR).

Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; members of the French Working Group on perioperative haemostasis (GIHP).

Anaesth Crit Care Pain Med. 2018 Aug;37(4):379-389. doi: 10.1016/j.accpm.2017.12.012. Epub 2018 Jan 5.

8.

Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.

Négrier C, Ducloy-Bouthors AS, Piriou V, De Maistre E, Stieltjes N, Borel-Derlon A, Colson P, Picard J, Lambert T, Claeyssens S, Boileau S, Bertrand A, André MH, Fourrier F, Ozier Y, Sié P, Gruel Y, Tellier Z.

Vox Sang. 2018 Feb;113(2):120-127. doi: 10.1111/vox.12624. Epub 2017 Dec 13.

PMID:
29238971
9.

Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies.

Vayne C, Guery EA, Kizlik-Masson C, Rollin J, Bauters A, Gruel Y, Pouplard C.

Br J Haematol. 2017 Dec;179(5):811-819. doi: 10.1111/bjh.14955. Epub 2017 Oct 19.

PMID:
29048130
10.

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; for FranceCoag Collaborators.

Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.

11.

Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.

Gouin-Thibault I, Freyburger G, de Maistre E, Susen S, Delavenne X, Golmard JL, Gruel Y, Sié P; GFHT study group on DOAC.

Thromb Res. 2017 Oct;158:126-133. doi: 10.1016/j.thromres.2017.09.001. Epub 2017 Sep 4.

PMID:
28892657
12.

[Neonatal arterial ischemic stroke: Which thrombotic biological risk factors to investigate and which practical consequences?]

Perez T, Valentin JB, Saliba E, Gruel Y.

Arch Pediatr. 2017 Sep;24(9S):9S28-9S34. doi: 10.1016/S0929-693X(17)30328-7. French.

PMID:
28867034
13.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.

PMID:
28815880
14.

5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.

Kizlik-Masson C, Vayne C, McKenzie SE, Poupon A, Zhou Y, Champier G, Pouplard C, Gruel Y, Rollin J.

J Thromb Haemost. 2017 Oct;15(10):2065-2075. doi: 10.1111/jth.13786. Epub 2017 Sep 4.

PMID:
28771917
15.

Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis.

Albaladejo P, Samama CM, Sié P, Kauffmann S, Mémier V, Suchon P, Viallon A, David JS, Gruel Y, Bellamy L, de Maistre E, Romegoux P, Thoret S, Pernod G, Bosson JL; GIHP-NACO Study Group.

Anesthesiology. 2017 Jul;127(1):111-120. doi: 10.1097/ALN.0000000000001631.

PMID:
28410272
16.

[Neonatal arterial ischemic stroke: Review of the current guidelines].

Saliba E, Debillon T; Recommandations accident vasculaire cérébral (AVC) néonatal, Auvin S, Baud O, Biran V, Chabernaud JL, Chabrier S, Cneude F, Cordier AG, Darmency-Stamboul V, Diependaele JF, Debillon T, Dinomais M, Durand C, Ego A, Favrais G, Gruel Y, Hertz-Pannier L, Husson B, Marret S, N'Guyen The Tich S, Perez T, Saliba E, Valentin JB, Vuillerot C.

Arch Pediatr. 2017 Feb;24(2):180-188. doi: 10.1016/j.arcped.2016.11.005. Epub 2016 Dec 20. French.

PMID:
28011082
17.

The Taipan snake venom time can be used to detect lupus anticoagulant in patients treated by rivaroxaban.

Pouplard C, Vayne C, Berthomet C, Guery EA, Delahousse B, Gruel Y.

Int J Lab Hematol. 2017 Jun;39(3):e60-e63. doi: 10.1111/ijlh.12611. Epub 2016 Dec 22. No abstract available.

PMID:
28004514
18.

Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors.

Rollin J, Pouplard C, Gruel Y.

Thromb Haemost. 2016 Oct 28;116(5):799-805. Epub 2016 Jun 30. Review.

PMID:
27358188
19.

Post-authorization safety study of Clottafact® , a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study.

Négrier C, Rothschild C, Borg JY, Lambert T, Claeyssens S, Sanhes L, Stieltjes N, Bertrand A, André MH, Sié P, Gruel Y, Tellier Z.

Vox Sang. 2016 Nov;111(4):383-390. doi: 10.1111/vox.12424. Epub 2016 Sep 1.

PMID:
27583698
20.

No impact of PTPN22, PTPRJ and ACP1 genes polymorphisms on the risk of immune thrombocytopenia in French adult patients.

Lioger B, Rollin J, Vayne C, Perret-Gallix K, Pouplard C, Godeau B, Michel M, Gruel Y.

Thromb Res. 2016 Aug;144:76-8. doi: 10.1016/j.thromres.2016.04.013. Epub 2016 Apr 25. No abstract available.

PMID:
27309885
21.

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.

Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T.

Pharmacogenomics. 2015 Dec;16(18):2035-43. doi: 10.2217/pgs.15.139. Epub 2015 Nov 30.

PMID:
26615857
22.

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial.

Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andréani C, Gruel Y, Morel J, Wynckel A, Grunebaum L, Villacorta-Torres J, Grosjean S, de Maistre E.

Crit Care. 2015 Nov 11;19:396. doi: 10.1186/s13054-015-1109-0.

23.

A rapid test (STic Expert® ) for the diagnosis of heparin-induced thrombocytopenia--response to De Cooman and Devreese.

Pouplard C, Gruel Y.

Br J Haematol. 2016 Feb;172(3):466-7. doi: 10.1111/bjh.13490. Epub 2015 May 11. No abstract available.

PMID:
25959988
24.

Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort.

Nurden AT, Pillois X, Fiore M, Alessi MC, Bonduel M, Dreyfus M, Goudemand J, Gruel Y, Benabdallah-Guerida S, Latger-Cannard V, Négrier C, Nugent D, Oiron RD, Rand ML, Sié P, Trossaert M, Alberio L, Martins N, Sirvain-Trukniewicz P, Couloux A, Canault M, Fronthroth JP, Fretigny M, Nurden P, Heilig R, Vinciguerra C.

Hum Mutat. 2015 May;36(5):548-61. doi: 10.1002/humu.22776.

25.

Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2.

Rollin J, Pouplard C, Sung HC, Leroux D, Saada A, Gouilleux-Gruart V, Thibault G, Gruel Y.

Blood. 2015 Apr 9;125(15):2397-404. doi: 10.1182/blood-2014-09-594515. Epub 2015 Feb 13.

26.

Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.

Lapalud P, Rothschild C, Mathieu-Dupas E, Balicchi J, Gruel Y, Laune D, Molina F, Schved JF, Granier C, Lavigne-Lissalde G.

J Thromb Haemost. 2015 Apr;13(4):540-7. doi: 10.1111/jth.12846. Epub 2015 Feb 27.

27.

A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.

Karnes JH, Cronin RM, Rollin J, Teumer A, Pouplard C, Shaffer CM, Blanquicett C, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Bakchoul T, Denny JC, Greinacher A, Gruel Y, Roden DM.

Thromb Haemost. 2015 Apr;113(4):772-81. doi: 10.1160/TH14-08-0670. Epub 2014 Dec 11.

28.

Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia.

Leroux D, Hezard N, Lebreton A, Bauters A, Suchon P, de Maistre E, Biron C, Huisse MG, Ternisien C, Voisin S, Gruel Y, Pouplard C.

Br J Haematol. 2014 Sep;166(5):774-82. doi: 10.1111/bjh.12939. Epub 2014 May 12.

PMID:
24815503
29.

Venous thromboembolism prophylaxis in patients undergoing abdominal or pelvic surgery for cancer--a real-world, prospective, observational French study: PRéOBS.

Samama CM, Boubli L, Coloby P, Debourdeau P, Gruel Y, Mariette C, Mottier D, Rischmann P, Toubiana L, Steib A.

Thromb Res. 2014 Jun;133(6):985-92. doi: 10.1016/j.thromres.2013.10.038. Epub 2013 Nov 1.

PMID:
24231117
30.

[Heparin-induced thrombocytopenia: recent data].

Gruel Y, Rollin J, Leroux D, Pouplard C.

Rev Med Interne. 2014 Mar;35(3):174-82. doi: 10.1016/j.revmed.2013.04.022. Epub 2013 Sep 26. Review. French.

PMID:
24074968
31.

[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P.

Ann Fr Anesth Reanim. 2013 Oct;32(10):691-700. doi: 10.1016/j.annfar.2013.04.016. Epub 2013 Aug 30. Review. French. Erratum in: Ann Fr Anesth Reanim. 2014 Mar;33(3):198-9.

PMID:
23993157
32.

Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.

May MA, Gruel Y, Fauchier L.

Circ Arrhythm Electrophysiol. 2013 Aug;6(4):e65. doi: 10.1161/CIRCEP.113.000515. Epub 2013 Jul 30. No abstract available.

PMID:
23899712
33.

Cerebral venous thrombosis in an elderly adult treated with diethylstilbestrol.

Ponce E, Cottier JP, Gruel Y, Hommet C, Mondon K.

J Am Geriatr Soc. 2013 Jul;61(7):1242-3. doi: 10.1111/jgs.12337. No abstract available.

PMID:
23855866
34.

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis.

Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):382-93. doi: 10.1016/j.acvd.2013.04.009. Epub 2013 Jun 25.

35.

Incidence of antibodies to protamine sulfate/heparin complexes incardiac surgery patients and impact on platelet activation and clinical outcome.

Pouplard C, Leroux D, Rollin J, Amiral J, May MA, Gruel Y.

Thromb Haemost. 2013 Jun;109(6):1141-7. doi: 10.1160/TH12-11-0844. Epub 2013 May 2.

PMID:
23636177
36.

Impact of polymorphisms affecting the ACP1 gene on levels of antibodies against platelet factor 4-heparin complexes.

Rollin J, Pouplard C, Leroux D, May MA, Gruel Y.

J Thromb Haemost. 2013 Aug;11(8):1609-11. doi: 10.1111/jth.12278. No abstract available.

37.

Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.

Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C.

Haemophilia. 2013 Mar;19(2):281-6. doi: 10.1111/hae.12018. Epub 2012 Oct 8.

PMID:
23038998
38.

Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis.

Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH; scientific and standardization committee of the international society on thrombosis and haemostasis.

J Thromb Haemost. 2011 Dec;9(12):2498-500. doi: 10.1111/j.1538-7836.2011.04536.x. No abstract available.

39.

The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII.

Lapalud P, Ali T, Cayzac C, Mathieu-Dupas E, Levesque H, Pfeiffer C, Balicchi J, Gruel Y, Borg JY, Schved JF, Granier C, Lavigne-Lissalde G.

J Thromb Haemost. 2012 Sep;10(9):1814-22. doi: 10.1111/j.1538-7836.2012.04850.x.

40.

Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.

Rollin J, Pouplard C, Gratacap MP, Leroux D, May MA, Aupart M, Gouilleux-Gruart V, Payrastre B, Gruel Y.

Blood. 2012 Aug 9;120(6):1309-16. doi: 10.1182/blood-2012-04-424044. Epub 2012 Jun 7.

41.

Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia.

Pouplard C, Cornillet-Lefebvre P, Attaoua R, Leroux D, Lecocq-Lafon C, Rollin J, Grigorescu F, Nguyen P, Gruel Y.

Thromb Res. 2012 Apr;129(4):465-9. doi: 10.1016/j.thromres.2011.09.033. Epub 2012 Jan 10.

PMID:
22239992
42.

Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay.

Leroux D, Canépa S, Viskov C, Mourier P, Herman F, Rollin J, Gruel Y, Pouplard C.

J Thromb Haemost. 2012 Mar;10(3):430-6. doi: 10.1111/j.1538-7836.2012.04618.x.

43.

Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.

Cayla G, Hulot JS, O'Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet JP.

JAMA. 2011 Oct 26;306(16):1765-74. doi: 10.1001/jama.2011.1529.

PMID:
22028352
44.

No association between the ITGA2 807T allele and retinopathy in french patients with type 2 diabetes.

Arsène S, Pouplard C, Perrodeau E, Delbachian I, Giraudeau B, Maillot F, Gruel Y.

Thromb Res. 2011 Sep;128(3):293-5. doi: 10.1016/j.thromres.2011.05.009. Epub 2011 Jun 1. No abstract available.

PMID:
21632096
45.

Bacteria and HIT: a close connection?

Gruel Y, Watier H.

Blood. 2011 Jan 27;117(4):1105-6. doi: 10.1182/blood-2010-11-317941.

46.

[Specificities of neonatal hemostasis and implications in pathologic situations].

Gruel Y.

Arch Pediatr. 2010 Sep;17 Suppl 3:S93-100. doi: 10.1016/S0929-693X(10)70907-6. French.

PMID:
20728815
47.

Comparative study of coagulation and thrombin generation in the portal and jugular plasma of patients with cirrhosis.

Delahousse B, Labat-Debelleix V, Decalonne L, d'Alteroche L, Perarnau JM, Gruel Y.

Thromb Haemost. 2010 Oct;104(4):741-9. doi: 10.1160/TH10-01-0040. Epub 2010 Aug 30.

PMID:
20806106
48.

Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies.

Pouplard C, Leroux D, Regina S, Rollin J, Gruel Y.

Thromb Haemost. 2010 Jan;103(1):145-50. doi: 10.1160/TH09-04-0253. Epub 2009 Sep 30.

PMID:
20062918
49.

TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.

Gaud G, Iochmann S, Guillon-Munos A, Brillet B, Petiot S, Seigneuret F, Touzé A, Heuzé-Vourc'h N, Courty Y, Lerondel S, Gruel Y, Reverdiau P.

J Cell Mol Med. 2011 Feb;15(2):196-208. doi: 10.1111/j.1582-4934.2009.00989.x.

50.

Tumor expression of alternatively spliced tissue factor is a prognostic marker in non-small cell lung cancer.

Rollin J, Regina S, Gruel Y.

J Thromb Haemost. 2010 Mar;8(3):607-10. doi: 10.1111/j.1538-7836.2009.03713.x. Epub 2009 Dec 3. No abstract available.

Supplemental Content

Support Center